Tecan and the Monash Antibody Technologies Facility Unveil Custom Monoclonal Antibody Production Facility
News Sep 17, 2008
The new Monash Antibody Technologies Facility (MATF) was officially opened on August 6th 2008 at a ceremony attended by a number of important dignitaries from the Australian government, academia and the life science industry.
The newly refurbished, two hundred square meter facility houses equipment, including 10 Freedom EVO® liquid handling workstations from Tecan, a global leader in laboratory automation and detection, and boasts impressive capabilities for high throughput production of custom-made, high-affinity monoclonal antibodies.
Michael Spiegel, deputy director of MATF, said: “In just one year, and with Tecan’s support, we have renovated a whole new space, brought in state-of-the-art, fully automated systems and have them already producing antibodies. This is now the largest capacity and probably the most sophisticated and technologically advanced custom antibody facility in the world. We already have 50 academic projects in the pipeline and we are members of the structural genomic consortium, an international pilot project for creating binding agents to all human proteins and protein binders.“
Alan Sawyer, Director of the facility, added: “We are finalizing several prestigious deals with companies and researchers from around the world, concerning the development of anywhere between two hundred and five hundred antibodies per year. This is truly an international facility.”
MATF, which is partially funded by the Victorian State Government, Monash University and the National Collaborative Research Infrastructure Strategy, is a major step towards an extensive 2008 development program which further strengthens Monash University’s rising profile as a centre of excellence in the international medical research community.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE